 |
Technical Support
(877) SEPAX-US, press 3  TechSupport@sepax-tech.com |
  |
| By Separation Mode | By Brand | By Sample Based Application | |
|
Size Exclusion Ion Exchange Hydrophobic Interaction Ion Exclusion Sub-2 UHPLC Purification Reversed Phase Mixed-mode Phase HILIC View All |
SEC-MALS Unix / Unix-C Zenix / Zenix-C SRT / SRT-C SRT-10 / SRT-10C Proteomix HIC / IEX Antibodix Carbomix Proteomix RP View All |
ADC Antibody Biosimilar Carbohydrate Cell Lysate DNA/RNA Fusion Protein Glycan Glycoprotein Heparin |
Insulin Membrane Protein Organic Acid PEG/PEGylated Protein Peptide Polymer Protein Vaccine/VLP Others |
How May We Help You?
How May We Help You?
How May We Help You?
Your question has been submitted.
We will respond back to you shortly.
We will respond back to you shortly.
How May We Help You?
Please fill out all required fields.
Samples
Sample: ADCADC Recommended products
Size Exclusion:
Zenix
Zenix-C
SRT
SRT-C
Preparative SEC
Ion Exchange: Proteomix Antibodix Proteomix AAV SAX Reversed phase: Proteomix RP Bio-C4 Hydrophobic Interaction: Proteomix HIC
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Application Note
Featured Application Notes
All Application Notes
| App ID | Title |
| ZM1019 | Analytical Characterization of Antibody Drug Conjugates | Size Exclusion@Ion Exchange@Reversed PhaseZenix-C@Proteomix@Proteomix RPMethod Optimization@Volatile Buffer@Packing Chemistry@Fast Assay@MAb Fragment@Charge Variants@Aggregates@Resolution@Competition Comparison@Orthogonal MethodHPLC@LCMS1
| LR2023011394 | Literature Reference: Hiding Payload Inside the IgG Fc Cavity Significantly Enhances the Therapeutic Index of Antibody Drug Conjugates | SECZenix-C SEC-300gsADCs@Glycosite-Specific Antibody Drug@Site-Specific ADCs on Sepax Analytical SEC HPLC1
| EM1003 | Herceptin Analysis on ZenixTM SEC-300 (7830) | Ion ExchangeZenixHerceptin AnalysisHPLC1
| WM1002 | ADC Separation on Unix-C SEC-300 | Size ExclusionUnix-CResolution@Aggregates@Competition Comparison@Column Stability@Lot to Lot@Particle Size Impact@LoadingUHPLC1
| ZM1024 | Intact MAb, ADC and their Fragment Analysis with SEC-MS | Size Exclusion@Size Exclusion@Size Exclusion@Size ExclusionZenix@Zenix-CMAb Fragment@Resolution@Volatile Buffer@Method Optimization HPLC@LCMS1
| ZM1023 | ADC vs. Free Drug Analysis | Size Exclusion@Size Exclusion@Size ExclusionZenix@Zenix-CResolution@Volatile Buffer@Pore Size Selection@Fast Assay@Method Optimization@Loading HPLC@LCMS1
| PM1016 | Intact MAb, ADC and their Fragments Analysis on RP LC/MS | Hydrophobic Interaction@Reversed Phase@Reversed PhaseProteomix HIC@Proteomix RPMAb Fragment@Resolution@Volatile Buffer@Method OptimizationHPLC@LCMS1
| ZM1022 | MAb/ADC Fragment Separation after IDeS Digestion | Size Exclusion@Size Exclusion@Hydrophobic Interaction@Reversed PhaseZenix@Zenix-C@Proteomix HIC@Proteomix RPMAb Fragment@Resolution@Volatile BufferHPLC/LCMS1
| HICM1001 | ADC/MAb Separation on Proteomix HIC | Hydrophobic InteractionProteomix@Proteomix HICLot to Lot@Competition Comparison@ResolutionHPLC1
| PM1013 | Intact and Reduced MAb/ADC and MAb Fragment Separation on RP | Reversed PhaseProteomix@Proteomix RPMethod Optimization@Volatile Buffer@Packing Chemistry@Fast Assay@MAb Fragment@Orthogonal MethodHPLC@LCMS@NanoLC1
| EM1004 | Herceptin-Lysine ADC Analysis by Zenix-C and TSKgel | Size ExclusionZenix-CCompetition Comparison@Resolution@Packing Chemistry@Aggregates@Method OptimizationHPLC1
| PM1011 | Herceptin-Cysteine ADC Charge Variants Separation on SCX | Ion ExchangeProteomixCharge VariantsHPLC1
| ZM1018 | MAb and its ADCs Separation on SEC | Size ExclusionZenix@Zenix-CResolution@Packing Chemistry@Aggregates@Method OptimizationHPLC1
| EM1002 | ADC Analysis on Zenix-C SEC | Size ExclusionZenix@Zenix-CResolution@Packing Chemistry@Aggregates@Method OptimizationHPLC1
| LR202202170 | Literature Reference: Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study | SECZenix-C SEC-300ADC, LC-MS Analysis, Organix Mobile Phase ACN:TFA:WaterHPLC@LC-MS1
| LR202202664 | Literature Reference: Homogeneous Antibody-Drug Conjugates: DAR 2 Anti-HER2 Obtained by Conjugation on Isolated Light Chain Followed by mAb Assembly | Size Exclusion, Hydrophobic InteractionZenix-C SEC-300@Proteomix HIC Butyl-NP5ADC, Heavy Chain and Light Chain AnalysisHPLC@HPLC1
| LR202202105 | Literature Reference: In-situ Reverse Phased HPLC Analysis of Intact Antibody-Drug Conjugates | Reversed PhaseProteomix RPADC (Antibody Drug Conjugate)HPLC2
| LR202202620 | Literature Reference: Design and Characterization of Homogenous Antibody-drug Conjugates with a Drug-to-Antibody Ratio of One Prepared Using an Engineered Antibody and a Dual-maleimide Pyrrolobenzodiazepine Dimer | Hydrophobic InteractionProteomix HICHydrophobic Interaction, Site-Specific ADC, DARHPLC2
| LR202202670 | Literature Reference: Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation | Hydrophobic InteractionProteomix HICHydrophobic Interaction, ADCHPLC2
| LR2023101483 | Literature Reference: Novel Thienoduocarmycin-trastuzumab ADC Demonstrates Strong Anti-tumor Efficacy | HICProteomix HICThienoduocarmycin-trastuzumab ADCHPLC2
| LR2022081354 | Design and Characterization of Immune-Stimulating Imidazo45-cquinoline Antibody Drug Conjugates | RPProteomix RPADC Free Drug Analysis on Sepax Analytical RP ColumnHPLC@UHPLC2